BerandaCRSP • NASDAQ
add
Crispr Therapeutics AG
$53,47
Setelah Jam Perdagangan Normal:(0,43%)+0,23
$53,70
Tutup: 28 Nov, 16.03.07 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$53,30
Rentang hari
$51,50 - $54,00
Rentang tahun
$30,06 - $78,48
Kapitalisasi pasar
5,10 M USD
Volume Rata-Rata
2,48 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 889,00 rb | 47,67% |
Biaya operasional | 68,26 jt | -22,11% |
Penghasilan bersih | -106,44 jt | -23,85% |
Margin laba bersih | -11,97 rb | 16,13% |
Penghasilan per saham | -1,17 | -15,84% |
EBITDA | -127,63 jt | -21,10% |
Tarif pajak efektif | -0,58% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,92 M | -1,03% |
Total aset | 2,25 M | -0,48% |
Total liabilitas | 329,33 jt | 4,06% |
Total ekuitas | 1,92 M | — |
Saham yang beredar | 95,30 jt | — |
Harga terhadap nilai buku | 2,61 | — |
Tingkat pengembalian aset | -15,45% | — |
Tingkat pengembalian modal | -16,29% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -106,44 jt | -23,85% |
Kas dari operasi | -84,63 jt | 20,84% |
Kas dari investasi | -119,23 jt | 26,22% |
Kas dari pembiayaan | 296,77 jt | 2.978,49% |
Perubahan kas bersih | 92,88 jt | 135,89% |
Arus kas bebas | -48,16 jt | 40,30% |
Tentang
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Didirikan
2013
Kantor pusat
Situs
Karyawan
393
